Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Thomas Karagiannis, Eleni Bekiari & Apostolos Tsapas. (2017) Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence 12, pages 1-10.
Read now
Read now
Sayf A Yassin & Vanita R Aroda. (2017) Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy 11, pages 923-937.
Read now
Read now
Tony B. Amos, Leslie Montejano, Paul Juneau & Susan C. Bolge. (2017) Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study. Journal of Medical Economics 20:3, pages 303-313.
Read now
Read now
Rong Qiu, Dainius Balis, John Xie, Michael J. Davies, Mehul Desai & Gary Meininger. (2017) Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion 33:3, pages 553-562.
Read now
Read now
Thomas C. Blevins & Azeez Farooki. (2017) Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine 129:1, pages 159-168.
Read now
Read now
Koutaro Yokote, Yasuo Terauchi, Ichiro Nakamura & Haruko Sugamori. (2016) Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opinion on Pharmacotherapy 17:15, pages 1995-2003.
Read now
Read now
Richard F. Arakaki. (2016) Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgraduate Medicine 128:4, pages 409-417.
Read now
Read now
Stanley S. Schwartz & Intekhab Ahmed. (2016) Sodium–glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. Current Medical Research and Opinion 32:5, pages 907-919.
Read now
Read now
Yasuo Terauchi, Koutaro Yokote, Ichiro Nakamura & Haruko Sugamori. (2016) Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study. Expert Opinion on Pharmacotherapy 17:4, pages 463-471.
Read now
Read now
Jochen Seufert. (2015) SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity 8, pages 543-554.
Read now
Read now
Orna Nitzan, Mazen Elias, Bibiana Chazan & Walid Saliba. (2015) Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes, Metabolic Syndrome and Obesity 8, pages 129-136.
Read now
Read now
Rosemarie Lajara. (2014) The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 15:17, pages 2565-2585.
Read now
Read now
Vidhya Jahagirdar & Anthony H Barnett. (2014) Empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:16, pages 2429-2441.
Read now
Read now
Jaime A. Davidson & Louis Kuritzky. (2014) Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine 126:6, pages 33-48.
Read now
Read now
Stephen Brunton & Timothy S. Reid. (2014) Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice 42:3, pages 96-108.
Read now
Read now
Keith Usiskin, Irina Kline, Albert Fung, Cristiana Mayer & Gary Meininger. (2014) Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results. Postgraduate Medicine 126:3, pages 16-34.
Read now
Read now
Articles from other publishers (51)
Rawa Bapir, Kamran Hassan Bhatti, Ahmed Eliwa, Herney Andrés García-Perdomo, Nazim Gherabi, Derek Hennessey, Vittorio Magri, Panagiotis Mourmouris, Adama Ouattara, Gianpaolo Perletti, Joseph Philipraj, Konstantinos Stamatiou, Musliu Adetola Tolani, Lazaros Tzelves, Stefan D. Anker, Alberto Trinchieri & Noor Buchholz. (2023) Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis. Archivio Italiano di Urologia e Andrologia 95:2.
Crossref
Crossref
Amy S. Shah, Philip S. Zeitler, Jencia Wong, Alexia S. Pena, Brandy Wicklow, Silva Arslanian, Nancy Chang, Junfen Fu, Preeti Dabadghao, Orit Pinhas‐Hamiel, Tatsuhiko Urakami & Maria E. Craig. (2022) ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatric Diabetes 23:7, pages 872-902.
Crossref
Crossref
Yao Wang, Xian Shao & Zewen Liu. (2022) Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly <i>versus</i> non-elderly patients with type 2 diabetes mellitus: a meta-analysis. Endocrine Journal 69:6, pages 669-679.
Crossref
Crossref
Angus Gill, Stephen P. Gray, Karin A. Jandeleit-Dahm & Anna M.D. Watson. (2019) SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. Current Diabetes Reviews 15:5, pages 349-356.
Crossref
Crossref
Zhang Jingfan, Li Ling, Liu Cong, Li Ping & Chen Yu. (2019) Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis. Archives of Endocrinology and Metabolism.
Crossref
Crossref
Mahakpreet Singh, Ruchika Sharma & Anoop Kumar. (2019) Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Current Drug Safety 14:2, pages 87-93.
Crossref
Crossref
Vishal Gupta, Michael Willis, Pierre Johansen, Andreas Nilsson, Manan Shah, Amey Mane & Cheryl Neslusan. (2019) Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues 18, pages 65-73.
Crossref
Crossref
Mortaza F. Hassanabad & Zahra F.H. Abad. (2019) Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:3, pages 1893-1896.
Crossref
Crossref
Izabela Rodrigues Figueiredo, Sara Cardoso Paes Rose, Nathália Bandeira Freire, Marina Stabile Patrocínio, Natália Pierdoná & Roberto José Bittencourt. (2019) Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review. Revista da Associação Médica Brasileira 65:2, pages 246-252.
Crossref
Crossref
Phillip Zeitler, Silva Arslanian, Junfen Fu, Orit Pinhas-Hamiel, Thomas Reinehr, Nikhil Tandon, Tatsuhiko Urakami, Jencia Wong & David M. Maahs. (2018) ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. Pediatric Diabetes 19, pages 28-46.
Crossref
Crossref
D. A. Lebedev & A. Yu. Babenko. (2018) Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia. Medical Council:16, pages 100-108.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Michael Willis, Pierre Johansen & Lien Vo. (2018) Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 9:2, pages 565-581.
Crossref
Crossref
Daniel J. Greene, Bradley C. Gill & Daniel A. Shoskes. (2017) Postoperative Urinary Tract Infection in a Patient With Iatrogenic Glucosuria. Urology 109, pages 3-5.
Crossref
Crossref
Jaime Davidson, Sanjay Kalra, Vikram Singh, Mayuresh Fegade, Gursimran Singh & Amey Mane. (2017) Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S159-S168.
Crossref
Crossref
Sonia Shoukat, Nida Arshad Usmani, Oluwakemi Soetan & Faisal Qureshi. (2017) Euglycemic Diabetic Ketoacidosis Accompanied by Severe Hypophosphatemia During Recovery in a Patient With Type 2 Diabetes Being Treated With Canagliflozin/Metformin Combination Therapy. Clinical Diabetes 35:4, pages 249-251.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
Richard E. Pratley & Eugenio Cersosimo. (2017) Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. Clinical Diabetes 35:3, pages 141-153.
Crossref
Crossref
Jian Li, Yanping Gong, Chunlin Li, Yanhui Lu, Yu Liu & Yinghong Shao. (2017) Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus. Medicine 96:27, pages e7201.
Crossref
Crossref
Matthew J. Budoff & John P. H. Wilding. (2017) Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. International Journal of Clinical Practice 71:5, pages e12948.
Crossref
Crossref
Paresh Dandona & Ajay Chaudhuri. (2017) Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. International Journal of Clinical Practice 71:5, pages e12937.
Crossref
Crossref
Norberto Perico, Piero Ruggenenti & Giuseppe Remuzzi. (2017) ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Current Opinion in Pharmacology 33, pages 34-40.
Crossref
Crossref
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt & Norman Waugh. (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment 21:2, pages 1-218.
Crossref
Crossref
Wei Xiong, Ming Yue Xiao, Mei Zhang & Fei Chang. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes. Medicine 95:48, pages e5473.
Crossref
Crossref
Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai & Kosei Kawamuki. (2016) Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials. Journal of Diabetes Investigation 7:4, pages 544-554.
Crossref
Crossref
Pamela Kushner. (2016) Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes. Women's Health 12:3, pages 379-388.
Crossref
Crossref
Gary C.W. Chan & Sydney C.W. Tang. (2016) Diabetic nephropathy: landmark clinical trials and tribulations. Nephrology Dialysis Transplantation 31:3, pages 359-368.
Crossref
Crossref
I. Dardi, T. Kouvatsos & S.A. Jabbour. (2016) SGLT2 inhibitors. Biochemical Pharmacology 101, pages 27-39.
Crossref
Crossref
May Sewify, Shinu Nair, Samia Warsame, Mohamed Murad, Asma Alhubail, Kazem Behbehani, Faisal Al-Refaei & Ali Tiss. (2016) Prevalence of Urinary Tract Infection and Antimicrobial Susceptibility among Diabetic Patients with Controlled and Uncontrolled Glycemia in Kuwait. Journal of Diabetes Research 2016, pages 1-7.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Pierre Johansen, Michael Willis, Atanacio Valencia-Mendoza & Andrea Puig. (2015) Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues 8, pages 8-19.
Crossref
Crossref
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
Xiang-Yang Liu, Ning Zhang, Rui Chen, Jia-Guo Zhao & Pei Yu. (2015) Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. Journal of Diabetes and its Complications 29:8, pages 1295-1303.
Crossref
Crossref
S. A. Brunton. (2015) The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. International Journal of Clinical Practice 69:10, pages 1071-1087.
Crossref
Crossref
Grzegorz Mizerski, Pawel Kicinski & Andrzej Jaroszynski. (2015) Flozins, inhibitors of type 2 renal sodium-glucose co-transporter – not only antihyperglycemic drugs. Current Issues in Pharmacy and Medical Sciences 28:3, pages 155-158.
Crossref
Crossref
Greg Fulcher, David R. Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Robert Weiss, Julio Rosenstock, George Capuano, Mehul Desai, Wayne Shaw, Frank Vercruysse, Gary Meininger & Bruce Neal. (2015) Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy 6:3, pages 289-302.
Crossref
Crossref
Xuekun Wang, Ying Li, Baowei Yang, Zheng Li, Wenlong Huang & Hai Qian. (2015)
C
-Aryl Glucosides with Substituents at the Distal Aryl Ring as Sodium-Dependent Glucose Cotransporter Inhibitors for the Treatment of Diabetes Mellitus
. Chemical Biology & Drug Design 86:2, pages 246-253.
Crossref
Crossref
Deborah Hinnen. (2015) Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism 6:3, pages 92-102.
Crossref
Crossref
S. Del Prato, M. Nauck, S. Durán‐Garcia, L. Maffei, K. Rohwedder, A. Theuerkauf & S. Parikh. (2015) Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes, Obesity and Metabolism 17:6, pages 581-590.
Crossref
Crossref
Gary Meininger, William Canovatchel, David Polidori & Norm Rosenthal. (2015) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 5:3, pages 183-201.
Crossref
Crossref
Deborah Hinnen. (2015) Short commentary on empagliflozin and its potential clinical impact. Therapeutic Advances in Endocrinology and Metabolism 6:2, pages 68-81.
Crossref
Crossref
John P.H. Wilding, Lawrence Blonde, Lawrence A. Leiter, Sonia Cerdas, Cindy Tong, Jacqueline Yee & Gary Meininger. (2015) Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and its Complications 29:3, pages 438-444.
Crossref
Crossref
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger & David Matthews. (2015) Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care 38:3, pages 403-411.
Crossref
Crossref
Curtis TriplittSusan Cornell. (2015) Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S31526.
Crossref
Crossref
Virginia Valentine & Deborah Hinnen. (2015) Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. Clinical Diabetes 33:1, pages 5-13.
Crossref
Crossref
B. Guerci. (2015) Les inhibiteurs de SGLT2 : pour quels patients ? Quelle place dans la stratégie thérapeutique ?. Médecine des Maladies Métaboliques 9:1, pages S49-S58.
Crossref
Crossref
B Haas, N Eckstein, V Pfeifer, P Mayer & M D S Hass. (2014) Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition & Diabetes 4:11, pages e143-e143.
Crossref
Crossref
J.-F. Yale, G. Bakris, B. Cariou, J. Nieto, E. David-Neto, D. Yue, E. Wajs, K. Figueroa, J. Jiang, G. Law, K. Usiskin & G. Meininger. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity and Metabolism 16:10, pages 1016-1027.
Crossref
Crossref
John P.H. Wilding. (2014) The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63:10, pages 1228-1237.
Crossref
Crossref
Qian Zhang, Jingtao Dou & Juming Lu. (2014) Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes Research and Clinical Practice 105:3, pages 313-321.
Crossref
Crossref
Greg L. Plosker. (2014) Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:7, pages 807-824.
Crossref
Crossref
Chang Hee JungJung Eun JangJoong-Yeol Park. (2014) A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes & Metabolism Journal 38:4, pages 261.
Crossref
Crossref
Hala Yamout, Vlado Perkovic, Melanie Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger & George Bakris. (2014) Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology 40:1, pages 64-74.
Crossref
Crossref